drugset / Trial / NCT04721223

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

NCT04721223

Phase 1/2 Completed 12 enrolled Jacobio Pharmaceuticals Co., Ltd. AbbVie · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.

Timeline

Start
2021-04-26
Primary completion
2023-12-29
Completion
2023-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-3068 Small molecule Oral
Subject Toripalimab Monoclonal antibody Intravenous